102 results
Page 2 of 6
8-K
EX-10.1
57zf jvmx0
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
DEFA14A
yv3ln2d e1gy
20 Sep 21
Additional proxy soliciting materials
2:53pm
8-K
voyi3xgvw49mb796c6ln
20 Sep 21
Regulation FD Disclosure
8:30am
PRE 14A
qpe3 w4s7ba
1 Sep 21
Preliminary proxy
4:46pm
8-K
EX-1.1
zk5nx
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
vva mxzw3lookz
15 Jul 21
Regulation FD Disclosure
9:54am
8-K
EX-10.1
skep3tjk1au
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
DEFA14A
9gf8e
26 Apr 21
Additional proxy soliciting materials
4:06pm
D
q7u0w05
19 Feb 21
$10.24M in equity / options, sold $10.24M, 18 investors
9:26am
8-K
EX-10.1
g67m1 xwslbfpvp96
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.2
lwgb9
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
4l07lfabs d0
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
y3x 4qro3moc
5 Oct 20
Prospectus supplement with pricing info
4:16pm